EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies

Eleonora Lalle, Valentina Mazzotta iD, Giuseppe Sberna iD, Lavinia Fabeni, Anna Rosa Garbuglia iD, Ilaria Mastrorosa iD, Alessandra D'Abramo iD, Emanuele Nicastri iD, Enrico Girardi iD, Andrea Antinori iD, Fabrizio Maggi iD, Licia Bordi

Viruses · 2024

DOI: 10.3390/v16071040 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Eleonora Lalle und 11 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy. Hauptthemen laut MEDLINE: Saliva, SARS-CoV-2, COVID-19, Ritonavir. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministero della Salute, Italian Ministry of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite emerging evidence indicating that molecular SARS-CoV-2 tests performed on saliva have diagnostic sensitivity and specificity comparable to those observed with nasopharyngeal swabs (NPSs), most in vivo follow-up studies on the efficacy of drugs against SARS-CoV-2 have been performed on NPSs, not considering saliva as a possible alternative matrix. For this reason, in this study, we used, in parallel, saliva and NPS samples for the detection of SARS-CoV-2 by real-time RT-PCR in patients receiving Tixagevimab/Cilgavimab, Nirmatrelvir/Ritonavir, or Sotrovimab as a treatment against SARS-CoV-2. Our results showed a good correlation between the NPS and saliva samples for each drug; moreover, comparable changes in the cycle threshold (Ct) levels in saliva and NPSs were observed both 7 days and 30 days after treatment, thus confirming that the saliva represents a good matrix for in vivo follow-up studies verifying the effectiveness of treatments against SARS-CoV-2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

SalivaSARS-CoV-2COVID-19RitonavirCOVID-19 Drug TreatmentNasopharynxSensitivity and SpecificityHumansFollow-Up StudiesAntiviral AgentsTreatment OutcomeAntibodies, Monoclonal, HumanizedDrug CombinationsLopinavirFemaleMaleCOVID-19 Nucleic Acid TestingMiddle Aged

Stichwörter der Autor:innen

COVID-19 diagnosisSARS-CoV-2antiviral therapyfollow-up studiesmolecular assaymonoclonal antibodiessaliva

Substanzen

RitonavirAntiviral AgentsAntibodies, Monoclonal, HumanizedDrug CombinationsLopinavirlopinavir-ritonavir drug combination

Autor:innen und Institutionen

  • Laboratory of Virology and Biosafety Laboratories, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Clinical and Research Department, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.
  • Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani-IRCCS, 00149 Rome, Italy.

ORCID-Profile: Valentina Mazzotta, Giuseppe Sberna, Anna Rosa Garbuglia, Ilaria Mastrorosa, Alessandra D'Abramo, Emanuele Nicastri, Enrico Girardi, Andrea Antinori, Fabrizio Maggi

Förderung

  • Ministero della Salute
  • Italian Ministry of Health

Zitieren

APA

Lalle, E., Mazzotta, V., Sberna, G., Fabeni, L., Garbuglia, A. R., Mastrorosa, I., D'Abramo, A., Nicastri, E., Girardi, E., Antinori, A., Maggi, F., & Bordi, L. (2024). Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies. Viruses. https://doi.org/10.3390/v16071040

Vancouver

Lalle E, Mazzotta V, Sberna G, Fabeni L, Garbuglia AR, Mastrorosa I, et al. Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies. Viruses. 2024. doi:10.3390/v16071040

BibTeX
@article{Lalle2024,
  author = {Lalle, Eleonora and Mazzotta, Valentina and Sberna, Giuseppe and Fabeni, Lavinia and Garbuglia, Anna Rosa and Mastrorosa, Ilaria and D'Abramo, Alessandra and Nicastri, Emanuele and Girardi, Enrico and Antinori, Andrea and Maggi, Fabrizio and Bordi, Licia},
  title = {Saliva Is a Sensitive and Accessible Sample Both for SARS-CoV-2 Detection and for the Evaluation of Treatment Effectiveness in Follow-Up Studies},
  journal = {Viruses},
  year = {2024},
  doi = {10.3390/v16071040}
}
Kostenlos starten →